- HK$7.41bn
- HK$9.91bn
- HK$4.17bn
Brief: SSY Group Test Kits Obtain Medical Device Registration In Hebei, China
Brief: SSY Group Obtains NMPA Approval For Fat-Soluble Vitamin Injection
Brief: SSY Group Obtains NMPA Approval For Diltiazem Hydrochloride For Injection
Brief: Ssy Group Says Upadacitinib Obtains Registration Approval From NMPA
Brief: Ssy Group Obtains NMPA Approvals
Brief: SSY Group Says Metoclopramide & Metoclopramide Hydrochloride Approved By China's NMPA
Chinese pharma group SSY sinks to 8-month low on weak earnings estimates
Brief: SSY Group Sees Reduction In FY Profit Attributable In Range Of 45% To 60%
Brief: SSY Group Updates On Phloroglucinol Trimethyl Ether And Dobutamine Hydrochloride
Brief: SSY Group Gets NMPA Approval For Drug Production And Registration For Perindopril Arginine And Amlodipine Besylate Tablets (III)
Brief: Ssy Group Obtains NMPA Approval For Sodium Glycerophosphate Injection Production
Brief: SSY Group Obtains Approval From China's NMPA For Levofloxacin Eye Drops
Brief: Ssy Group Says Finerenone Has Obtained Approval For Registration From NMPA
Brief: Ssy Group Says Bilastine And Sodium Picosulfate Approved In China
Brief: SSY Group Gets Approval For Drug Production & Registration For Tolterodine Tartrate Sustained-Release Capsules From China's NMPA
Brief: SSY Group Says Vitamin A Palmitate Approved In China
Brief: SSY Group Says Obtains Approval For Aminophylline Tablets From Nmpa
Brief: SSY Group Obtains Approval For Indobufen Tablets By NMPA China
Brief: SSY Group Says 3 Bulk Drugs Obtain NMPA Approvals To Become Bulk Drugs For Preparations On Market